News - Research, Diabetes

Filter

Current filters:

ResearchDiabetes

Popular Filters

1 to 25 of 146 results

ImmuPharma extends research capabilities via French connection

27-06-2014

UK-based drug discovery firm ImmuPharma has extended its research capabilities by setting up its own…

DiabetesImmuPharmaPharmaceuticalResearchUrelix

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

ADA 2014: Positive Ph III Results for Sanofi’s Toujeo

ADA 2014: Positive Ph III Results for Sanofi’s Toujeo

15-06-2014

French pharma major Sanofi has released data from a pooled analysis, investigational therapy Toujeo (insulin…

DiabetesPharmaceuticalResearchSanofiToujeo

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

15-06-2014

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide),…

Anti-diabetic drugsDiabetesGlaxoSmithKlineGSKMajorPharmaceuticalResearchStudy protocolStudy protocolTanzeumUK

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

30-05-2014

Anglo-Swedish pharma major AstraZeneca has announced that Bydureon (exenatide once-weekly injection)…

Anti-diabetic drugsAstraZenecaBydureonDiabetesGlucagonPharmaceuticalResearchUK

Significantly greater weight loss versus placebo seen in Ph IIIa study of liraglutide 3mg

16-05-2014

Significant weight loss was demonstrated for Danish insulin giant Novo Nordisk’s diabetes drug liraglutide…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

GW Pharmaceuticals updates on cannabinoid pipeline

GW Pharmaceuticals updates on cannabinoid pipeline

17-03-2014

UK biopharma company GW Pharmaceuticals this morning provided an update on the company’s cannabinoid…

DiabetesepidiolexGW PharmaceuticalsGWP42004GWP42006NeurologicalPharmaceuticalResearchSativex

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

Australian patients benefit from PBS changes; cancer research

27-02-2014

New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing…

Asia-PacificAustraliaDiabetesFinancialHealthcareKombiglyzeOncologyPharmaceuticalResearchTrajentaVotrient

Positive results for MicroBiome’s NM504 in type 2 diabetes

18-02-2014

Privately-held US biotech company MicroBiome Therapeutics has released positive top-line results from…

BiotechnologyDiabetesMicroBiome TherapeuticsNM504Research

Nearly 200 new medicines in development for diabetes by US drugmakers

12-02-2014

The USA’s biopharmaceutical research companies are currently developing 180 innovative new medicines…

DiabetesNorth AmericaPharmaceuticalResearch

FDA to review heart failure risk with AstraZeneca diabetes drug

FDA to review heart failure risk with AstraZeneca diabetes drug

12-02-2014

The US Food and Drug Administration has requested clinical trial data from Anglo-Swedish drug major AstraZeneca,…

AstraZenecaDiabetesKombiglyzeNorth AmericaOnglyzaPharmaceuticalRegulationResearchUSA

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

11-02-2014

US pharma giant Merck & Co and South Korea’s Samsung Bioepis have expanded their collaboration with…

BiosimilarsDiabetesInsulin Glargine [rDNA origin] InjectionLantusLicensingMerck & CoPharmaceuticalResearchSamsung BioepisSanofi

Oramed announces successful Phase IIa clinical trial results

30-01-2014

Israeli drugmaker Oramed Pharmaceuticals (NasdaqCM: ORMP) has announced positive results from the Phase…

DiabetesEastern EuropeOramedPharmaceuticalResearch

“Differing views” see Zealand and Boehringer change collaboration compound

“Differing views” see Zealand and Boehringer change collaboration compound

20-01-2014

Zealand Pharma and Boehringer Ingelheim will change the development program involving novel glucagon/GLP-1…

Boehringer IngelheimDenmarkDiabetesGermanyPharmaceuticalResearchZealand Pharma

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

16-01-2014

Denmark’s Zealand Pharma says it has achieved a milestone under its collaboration with French drug…

DiabetesFinancialLixiLanLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

27-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has decided voluntarily to terminate the development…

DiabetesfasiglifamGastro-intestinalsNorth AmericaPharmaceuticalRegulationResearchTakeda PharmaceuticalsUSAvedolizumab

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

05-12-2013

Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

1 to 25 of 146 results

Back to top